Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Emery

Showing results (31-40 of 731) with videos related to

Pageof 74
Sort By:
Expert Opinion on Biological Therapy|September 3, 2013
Etanercept in the treatment of rheumatoid arthritisLaura Hunt, Paul Emery
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Anti-Porphyromonas gingivalis Antibodies in Rheumatoid Arthritis: Comment on the Article by Seror et alKulveer Mankia, Paul Emery
Arthritis and Rheumatism|September 28, 2010
The American College of Rheumatology/European League Against Rheumatism criteria for the classification of rheumatoid arthritis: a game changerStanley Cohen, Paul Emery
Best Practice & Research. Clinical Rheumatology|December 10, 2017
What can palindromic rheumatism tell us?Kulveer Mankia, Paul Emery
Joint Bone Spine|March 27, 2007
The role of MRI and ultrasound as surrogate markers of structural efficacy of treatments in rheumatoid arthritisJane Freeston, Paul Emery
Expert Review of Clinical Immunology|May 19, 2010
Use of prognostic markers in early rheumatoid arthritis to identify patients at risk of destructive diseaseSally Cox, Paul Emery
Arthritis and Rheumatism|August 20, 2010
Delay in receiving rheumatology care leads to long-term harmVivian Bykerk, Paul Emery
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Preclinical Rheumatoid Arthritis: Progress Toward PreventionKulveer Mankia, Paul Emery
Expert Opinion on Investigational Drugs|November 29, 2021
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trialsLeticia Garcia-Montoya, Paul Emery
Arthritis Research & Therapy|June 1, 2011
Infliximab: 12 years of experienceJosef S Smolen, Paul Emery
Pageof 74

Showing results (31-40 of 731) with videos related to

Sort By:
Pageof 74
Expert Opinion on Biological Therapy|September 3, 2013
Etanercept in the treatment of rheumatoid arthritisLaura Hunt, Paul Emery
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2015
Anti-Porphyromonas gingivalis Antibodies in Rheumatoid Arthritis: Comment on the Article by Seror et alKulveer Mankia, Paul Emery
Arthritis and Rheumatism|September 28, 2010
The American College of Rheumatology/European League Against Rheumatism criteria for the classification of rheumatoid arthritis: a game changerStanley Cohen, Paul Emery
Best Practice & Research. Clinical Rheumatology|December 10, 2017
What can palindromic rheumatism tell us?Kulveer Mankia, Paul Emery
Joint Bone Spine|March 27, 2007
The role of MRI and ultrasound as surrogate markers of structural efficacy of treatments in rheumatoid arthritisJane Freeston, Paul Emery
Expert Review of Clinical Immunology|May 19, 2010
Use of prognostic markers in early rheumatoid arthritis to identify patients at risk of destructive diseaseSally Cox, Paul Emery
Arthritis and Rheumatism|August 20, 2010
Delay in receiving rheumatology care leads to long-term harmVivian Bykerk, Paul Emery
Arthritis & Rheumatology (Hoboken, N.J.)|January 28, 2016
Preclinical Rheumatoid Arthritis: Progress Toward PreventionKulveer Mankia, Paul Emery
Expert Opinion on Investigational Drugs|November 29, 2021
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trialsLeticia Garcia-Montoya, Paul Emery
Arthritis Research & Therapy|June 1, 2011
Infliximab: 12 years of experienceJosef S Smolen, Paul Emery
Pageof 74